The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta

Abstract A nonmedical switch policy is currently being considered in Alberta, which would force patients on originator biologics to biosimilar alternatives with the hypothetical aim of reducing costs to the health care system. The evidence to support the safety of nonmedical switching in patients with inflammatory bowel disease (IBD) is of low to very low quality; in fact, existing data suggest a potential risk of harm. In a pooled analysis of randomized controlled trials, one patient would lose response to infliximab for every 11 patients undergoing nonmedical switching. Switching to a biosimilar has important logistical and ethical implications including potential forced treatment changes without appropriate patient consent and unfairly penalizing patients living in rural areas and those without private drug insurance. Even in the best-case scenario, assuming perfectly executed switching without logistical delays, we predict switching 2,000 patients with Remicade will lead to over 60 avoidable surgeries in Alberta. Furthermore, nonmedical switching has not been adequately studied in vulnerable populations such as children, pregnant women, and elderly patients. While the crux of the argument for nonmedical switching is cost savings, biosimilar switching may not be cost effective: Particularly when originator therapies are being offered at the same price as biosimilars. Canadian patients with IBD have been surveyed, and their response is clear: They are not in support of nonmedical switching. Policies that directly influence patient health need to consider patient perspectives. Solutions to improve cost efficiency in health care exist but open, transparent collaboration between all involved stakeholders is required.

[1]  T. Caulfield,et al.  The Law and Ethics of Switching from Biologic to Biosimilar in Canada , 2020, Journal of the Canadian Association of Gastroenterology.

[2]  P. Moayyedi,et al.  Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease , 2019, Journal of the Canadian Association of Gastroenterology.

[3]  H. El‐Serag,et al.  Recommendations for Successful Transition of Adolescents With Inflammatory Bowel Diseases to Adult Care. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Siddharth Singh,et al.  Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old or Obstetric. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  S. Ghaly,et al.  Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study , 2019 .

[6]  S. Vermeire,et al.  Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. , 2019, Inflammatory bowel diseases.

[7]  D. Mitsikostas,et al.  Nocebo in Biosimilars and Generics in Neurology: A Systematic Review , 2019, Front. Pharmacol..

[8]  S. Coward Forecasting the Future: A Trek through the Changing Landscape of Inflammatory Bowel Disease , 2019 .

[9]  M. Skup,et al.  Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review , 2019, Advances in Therapy.

[10]  S. Ng,et al.  Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. , 2019, The lancet. Gastroenterology & hepatology.

[11]  G. Kaplan,et al.  Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. , 2019, Gastroenterology.

[12]  G. Veres,et al.  Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN , 2019, Journal of pediatric gastroenterology and nutrition.

[13]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization , 2018, Journal of the Canadian Association of Gastroenterology.

[14]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada , 2018, Journal of the Canadian Association of Gastroenterology.

[15]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors , 2018, Journal of the Canadian Association of Gastroenterology.

[16]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology , 2018, Journal of the Canadian Association of Gastroenterology.

[17]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD , 2018, Journal of the Canadian Association of Gastroenterology.

[18]  S. Vermeire,et al.  Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease , 2019, Therapeutic drug monitoring.

[19]  M. Skup,et al.  Short-term costs associated with non-medical switching in autoimmune conditions. , 2019, Clinical and experimental rheumatology.

[20]  L. Peyrin-Biroulet,et al.  Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. , 2019, Current medicinal chemistry.

[21]  M. Calleja,et al.  Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease , 2018, World journal of gastroenterology.

[22]  C. Lees,et al.  Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes , 2018, Digestive Diseases and Sciences.

[23]  G. Kaplan,et al.  Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression , 2018, Gut.

[24]  Gregory A. Heindel,et al.  The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies , 2018, Journal of managed care & specialty pharmacy.

[25]  L. Peyrin-Biroulet,et al.  The nocebo effect: a clinical challenge in the era of biosimilars , 2018, Expert review of clinical immunology.

[26]  M. Regueiro,et al.  ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.

[27]  Sandra C. Kim,et al.  Assuring Quality for Non-hospital–based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition , 2018, Journal of pediatric gastroenterology and nutrition.

[28]  Y. Choe,et al.  Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study. , 2018, Inflammatory bowel diseases.

[29]  S. Vermeire,et al.  Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.

[30]  Subrata Ghosh,et al.  Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study , 2017, The American Journal of Gastroenterology.

[31]  D. Rubin,et al.  Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors , 2017, Current medical research and opinion.

[32]  K. Phillips,et al.  SAT0172 Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or ct-p13 in the turkish population , 2017 .

[33]  L. Downey,et al.  Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme , 2017, Journal of Crohn's & colitis.

[34]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[35]  D. Roccatello,et al.  Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review , 2017, BioDrugs.

[36]  C. Piech,et al.  Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review , 2016, Current medical research and opinion.

[37]  A. Bitton,et al.  The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.

[38]  G. Kaplan,et al.  Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. , 2015, Gastroenterology.

[39]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[40]  G. Kaplan,et al.  Postoperative complications and mortality following colectomy for ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  S. Ben-Horin,et al.  Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[42]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[43]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[44]  J. Mawdsley,et al.  RECENT ADVANCES IN BASIC SCIENCE PSYCHOLOGICAL STRESS IN IBD: NEW INSIGHTS INTO PATHOGENIC AND THERAPEUTIC IMPLICATIONS , 2005 .